Hypothalamic Obesity Clinical Trial
Official title:
A Randomized, Placebo-controlled, Double-Blind Phase 2 Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity, With an Open-Label Extension
The goal of this study is to determine how well LB54640 works and how safe it is in patients with Hypothalamic Obesity (HO). The study will evaluate the effect of LB54640 on safety, weight reduction, hunger, and quality of life in patients 12 years of age and older with HO. Patients will take an oral daily dose of either LB54640 (low, middle, or high dose) or placebo through Week 14. Eligible patients who consent to continue in the study after Week 14 will take an oral daily dose of LB54640 through Week 56.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02849743 -
Intranasal Oxytocin in Hypothalamic Obesity
|
Phase 2 | |
| Recruiting |
NCT06217848 -
The Effect of GLP-1 Agonist in Patients With Hypothalamic Obesity: Prospective, Pilot Study
|
Early Phase 1 | |
| Withdrawn |
NCT05147415 -
Study of Tesomet With Open-label Extension in Subjects With Hypothalamic Obesity (HO)
|
Phase 2 | |
| Completed |
NCT00892073 -
Hypothalamic Obesity Following Craniopharyngioma Surgery: A Pilot Trial of Combined Metformin and Diazoxide Therapy
|
Phase 2 | |
| Not yet recruiting |
NCT06299891 -
Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity
|
Phase 2 | |
| Recruiting |
NCT06239116 -
A Study of RM-718 in Healthy Subjects and in Patients With HO
|
Phase 1 | |
| Completed |
NCT02664441 -
Energy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic Obesity
|
Phase 3 | |
| Completed |
NCT04725240 -
Open-Label Study of Setmelanotide in Hypothalamic Obesity
|
Phase 2 | |
| Completed |
NCT03673813 -
A Personalized Program of Physical Activity and Diet for Hypothalamic Obesity
|
||
| Withdrawn |
NCT03708913 -
Neuromodulation for Hypothalamic Obesity
|
N/A | |
| Completed |
NCT01061775 -
Effects of Exenatide on Hypothalamic Obesity
|
Phase 1/Phase 2 | |
| Completed |
NCT02860923 -
Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy
|
Phase 3 | |
| Completed |
NCT00171613 -
A Study of Octreotide Depot vs Saline Control in Pediatric Hypothalamic Obesity Patients
|
Phase 4 | |
| Recruiting |
NCT01783717 -
Effects of Exenatide on Obesity and/or Diabetes Mellitus Due to Hypothalamic Damage
|
N/A | |
| Enrolling by invitation |
NCT05774756 -
A Trial of Setmelanotide in Acquired Hypothalamic Obesity
|
Phase 3 | |
| Completed |
NCT05319301 -
Identification and Clinical Relevance of an Oxytocin Deficient State (Melatonin Study)
|
N/A |